Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Desfesoterodine→

Desfesoterodine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
207679-81-0
Molecular formula
C22H31NO2
Molecular weight
341.5 g/mol
Drug class
Active metabolite of fesoterodinemuscarinic acetylcholine receptor antagonist
Mechanism of action
The active metabolite 5-hydroxymethyltolterodine competitively antagonises muscarinic receptors on bladder detrusor smooth muscle, reducing acetylcholine-mediated involuntary contractions and increasing functional bladder capacity.
Indications / reported uses
  • The clinically marketed prodrug fesoterodine is used for overactive bladder in adults and selected paediatric patients. Desfesoterodine is the active metabolite and is not usually marketed as an independent API; do not assign it a separate standalone indication.

Sources: US DailyMed — TOVIAZ (fesoterodine) · NLM MeSH — 5-Hydroxymethyltolterodine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Desfesoterodine Environmental Risk Assessment (ERA) (the Desfesoterodine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.